Listen: Biotech Firms Set Their Funding Sights High


The arrival of the new year also brings with it, the arrival of new products in the marketplace. Of specific interest this year are several biotech firms that have their funding sights set fairly high. While 2016 and the 1st quarter of 2017 were somewhat bleak for the industry financially speaking, there was a definite uptick beginning in the 2nd quarter of 2017. The Redwood City, California firm, ARMO BioSciences is gathering funding for its white-blood cell boosting immunotherapy offering. On the other coast, Cambridge, Massachusetts-based laboratory, Solid, is moving forward with its gene-transfer therapy aimed at Duchenne Muscular Dystrophy.  Finally, anti-aging research continues right down the road at resTORbio, in Boston.  These 3 biotech companies are aiming to acquire approximately $271 million in capital this year to continue their research and development.

Follow us on social media for the latest updates in B2B!


Main Street’s Looking Pretty Sunny These Days
October 7, 2022
On Tuesday, September 13, 2022, the Dow dropped 3.94% after an August inflation report indicated a 0.1% month-over-month rise. Tech stocks bared a large brunt of the losses, with Meta dropping 9.4% Read more
What Brand Intimacy Means for Consumers
October 7, 2022
What immediately pops up in your head when you hear the word intimacy? Definitely, not food, said Barbara Castiglia of the podcast “Modern Restaurant Management.” But that may change thanks to a Read more
adaptive reuse hotel-to-apartment conversions
Are Hotel-to-Apartment Adaptive Reuse Conversions Worth the Investment?
October 7, 2022
The need for affordable housing, especially in major cities, is a constant challenge for tenants, an often-nebulous investment for developers, and a point of contention for city officials. A recent trend Read more